Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504575 | 1.00 | PTGS2 (0.70) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14504615 | 0.92 | PTGS2 (0.64) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL14504613 | 0.91 | PTGS2 (0.66) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14504559 | 0.91 | PTGS2 (0.70) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5150634 | 0.90 | PTGS2 (0.57) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14504560 | 0.88 | PTGS2 (0.70) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5149036 | 0.88 | PTGS2 (0.54) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14505127 | 0.87 | PTGS2 (0.71) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14504870 | 0.87 | PTGS2 (0.74) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14504605 | 0.87 | PTGS2 (0.68) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | PTGS2 1780/4885PTGS1 1105/4885CYP1A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.